CD8A and neoplasm: Other immunotherapies that provide survival benefits utilize the checkpoint inhibitors (anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies), which block CD8+ T-cell inhibition promoted by the immunosuppressive tumour environment9.